CRNO B — Cereno Scientific AB Share News
0.000.00%
- SEK1.11bn
- SEK1.25bn
Brief: Cereno Scientific Receives SEK 4 Mln Through Exercise Of Warrants
Brief: Cereno Scientific Submits Trial Protocol To U.S. FDA
Brief: Cereno Scientific Q2 Loss After Financial Items At SEK 26.6 Million
Brief: Cereno Scientific Granted FDA Fast Track For CS1 In PAH Treatment
Brief: Cereno Announces Positive Results From Phase I Trial Of Cs014
Brief: Cereno Scientific Signs Agreement With Global Cro
Brief: Cereno Scientific Secures SEK 100 Mln Through Loan Financing, Conversion To Advance HDAC Inhibitors
Brief: Cereno Scientific Q1 Loss After Financial Items Widens TO SEK 25 Mln
Brief: Cereno Scientific Extends Patent Protection For Drug Candidate CS1 In U.S.
Brief: Cereno Scientific Lead Candidate CS1 Trial Meets Primary Endpoint
Brief: Cereno Scientific Q4 Adjusted EPS Is SEK -0.14
Brief: Cereno Scientific Drug Candidate Cs014 Completes First Part Of Phase I Trial
Brief: Cereno Scientific Q3 Loss After Financial Items SEK 22.7 Mln
Brief: Cereno Scientific Signs Agreement With Fluidda
Brief: Cereno Scientific Announces Positive Topline Results Of Phase Iia Trial With Lead Candidate Cs1 In Pulmonary Arterial Hypertension
Brief: Cereno Scientific - New Preclinical Data Show Dose Dependent Positive Impact On Reversal Of Pulmonary Vascular Remodeling By Novel HDACi CS014
Brief: Cereno Scientific Expands Patent Protection For CS585 In China
Brief: Cereno Scientific Granted OMPD For CS1 In Rare Disease Pulmonary Arterial Hypertension
Brief: Cereno Scientific Q2 Loss After Financial Items Widens To SEK 21.2 Mln